Acorda Therapeutics, Inc. received approval from the FDA for Ampyra (dalfampridine) to improve walking in patients with multiple sclerosis (MS). Ampyra is an extended release tablet formulation of the investigational drug dalfampridine (4-aminopyridine and called fampridine outside the U.S.). Ampyra will be marketed by Acorda Therapeutics, Inc. in the U.S. and Biogen Idec will commercialize fampridine as a prolonged release tablet in markets outside of the U.S. Ampyra was developed using Elan...